scholarly journals Prognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly

PLoS ONE ◽  
2015 ◽  
Vol 10 (5) ◽  
pp. e0126357 ◽  
Author(s):  
Agnes Csanadi ◽  
Claudia Kayser ◽  
Marcel Donauer ◽  
Vera Gumpp ◽  
Konrad Aumann ◽  
...  
2005 ◽  
Vol 23 (28) ◽  
pp. 6865-6872 ◽  
Author(s):  
Paolo Maione ◽  
Francesco Perrone ◽  
Ciro Gallo ◽  
Luigi Manzione ◽  
FrancoVito Piantedosi ◽  
...  

Purpose To study the prognostic value for overall survival of baseline assessment of functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non—small-cell lung cancer treated with chemotherapy. Patients and Methods Data from 566 patients enrolled onto the phase III randomized Multicenter Italian Lung Cancer in the Elderly Study (MILES) study were analyzed. Functional status was measured as activities of daily living (ADL) and instrumental ADL (IADL). The presence of comorbidity was assessed with a checklist of 33 items; items 29 and 30 of the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 (EORTC QLQ-C30) were used to estimate QoL. ADL was dichotomized as none versus one or more dependency. For IADL and QoL, three categories were defined using first and third quartiles as cut points. Comorbidity was summarized using the Charlson scale. Analysis was performed by Cox model, and stratified by treatment arm. Results Better values of baseline QoL (P = .0003) and IADL (P = .04) were significantly associated with better prognosis, whereas ADL (P = .44) and Charlson score (P = .66) had no prognostic value. Performance status 2 (P = .006) and a higher number of metastatic sites (P = .02) also predicted shorter overall survival. Conclusions Pretreatment global QoL and IADL scores, but not ADL and comorbidity, have significant prognostic value for survival of elderly patients with advanced non—small-cell lung cancer who were treated with chemotherapy. Using these scores in clinical practice might improve prognostic prediction for treatment planning.


2008 ◽  
Vol 68 (20) ◽  
pp. 8547-8554 ◽  
Author(s):  
Toshiro Migita ◽  
Tadahito Narita ◽  
Kimie Nomura ◽  
Erika Miyagi ◽  
Fumika Inazuka ◽  
...  

Lung Cancer ◽  
2004 ◽  
Vol 46 (1) ◽  
pp. 125-126
Author(s):  
Stefano Margaritora ◽  
Alfredo Cesario ◽  
Domenico Galetta ◽  
Venanzio Porziella ◽  
Silvia Sterzi ◽  
...  

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Xiaoshan Su ◽  
Ning Liu ◽  
Weijing Wu ◽  
Zhixing Zhu ◽  
Yuan Xu ◽  
...  

Abstract Background Kindlin Family Members have been reported to be aberrantly expressed in various human cancer types and involved in tumorigenesis, tumor progression, and chemoresistance. However, their roles in non-small cell lung cancer (NSCLC) remain poorly elucidated. Methods We analyzed the prognostic value and immune infiltration of Kindlins in NSCLC through Oncomine, GEPIA, UALCAN, CCLE, Kaplan‑Meier plotter, cBioPortal, TIMER, GeneMANIA, STRING, and DAVID database. Additionally, the mRNA expression levels of Kindlins were verified in 30 paired NSCLC tissues and NSCLC cell lines by real-time PCR. Results The expression level of FERMT1 was remarkably increased in NSCLC tissues and NSCLC cell lines, while FERMT2 and FERMT3 were reduced. Kindlins expressions were associated with individual cancer stages and nodal metastasis. We also found that higher expression level of FERMT1 was obviously correlated with worse overall survival (OS) in patients with NSCLC, while higher FERMT2 was strongly associated with better overall survival (OS) and first progression (FP). Additionally, the expression of FERMT2 and FERMT3 were obviously correlated with the immune infiltration of diverse immune cells. Functional enrichment analysis has shown that Kindlins may be significantly correlated with intracellular signal transduction, ATP binding and the PI3K-Akt signaling pathway in NSCLC. Conclusions The research provides a new perspective on the distinct roles of Kindlins in NSCLC and likely has important implications for future novel biomarkers and therapeutic targets in NSCLC.


Biomarkers ◽  
2006 ◽  
Vol 11 (3) ◽  
pp. 262-269 ◽  
Author(s):  
E. Jassem ◽  
K. Serkies ◽  
R. Dziadziuszko ◽  
A. Drozdowska ◽  
G. Kobierska-Gulida ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document